HONG KONG — Sisram Medical Ltd (“Sisram” or the “Company”; stock code: 1696.HK), an investment holding company specializing in medical technology for healthcare ranked #1 in the PRC and one of the top 5 global leaders in the industry, announced the increase in shareholding by the Company’s controlling shareholder and CEO.
Ample Up Limited (“Ample Up”), controlling shareholder of Sisram, and Mr. Lior Moshe Dayan, Chief Executive Officer and Executive Director of Sisram, has acquired additional shares of the Company. According to latest announcements, Ample Up has made on-market purchase on The Stock Exchange of Hong Kong Limited (“SEHK”) of an aggregate of 288,800 and 270,000 shares of the Company on 21 and 22 November 2017 respectively. Mr. Dayan has made on-market purchases on SEHK of an aggregate of 36,000 shares of the Company. After the increase in shareholding, Ample Up directly and indirectly controls approximately 52.83% and Mr. Dayan controls approximately 0.008% of the total issued shares of the Company.
In the first half of 2017, the Company’s revenue was reported US$66.3 million, representing a year over year growth of 12.9%. The Company’s adjusted net profit increased by 30.6% to US$13.3 million. The profitability and operational quality of the Company improved continuously. Sisram invest a lot of efforts in promoting its various brands, increasing market awareness and sales of its products, as well as expanding sales and distribution channels. The increase of shareholdings by the company’s controlling shareholder and management expresses a vote of confidence in the company and its future roadmap.
Looking forward, Mr. Lior Moshe Dayan said, “Sisram is the first Israeli company listed on the main board of the Hong Kong Stock Exchange, with comprehensive in-house capabilities to design, develop and produce energy-based medical aesthetic treatment systems. In the past 3 years, more than 90% of our revenue was driven from products that we have developed in-house. Moving forward we are committed to significant investments in Research & Development that will produce innovative high-end products to meet the growing opportunities that the global market of energy-based medical aesthetic treatment solutions presents.”